Blurbs

B.Riley Financial Remains a Buy on Agenus (AGEN)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Agenus (AGENResearch Report), with a price target of $8.00. The company’s shares opened today at $2.66.

Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Agenus, and Arrowhead Pharmaceuticals. According to TipRanks, Mamtani has an average return of -23.8% and a 27.71% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agenus with a $8.00 average price target.

See the top stocks recommended by analysts >>

AGEN market cap is currently $738.3M and has a P/E ratio of (28.09).

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Read More on AGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed